| Molecular biomarkers for lung adenocarcinoma O Calvayrac, A Pradines, E Pons, J Mazières, N Guibert European Respiratory Journal 49 (4), 2017 | 151 | 2017 |
| Targeting PI3K signaling in combination cancer therapy E Pons-Tostivint, B Thibault, J Guillermet-Guibert Trends in cancer 3 (6), 454-469, 2017 | 146 | 2017 |
| Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck K Saleh, A Daste, N Martin, E Pons-Tostivint, A Auperin, ... European Journal of Cancer 121, 123-129, 2019 | 145 | 2019 |
| Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases W Jacot, E Pons, JS Frenel, S Guiu, C Levy, PE Heudel, T Bachelot, ... Breast cancer research and treatment 157, 307-318, 2016 | 123 | 2016 |
| Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY … K Goto, Y Goto, T Kubo, K Ninomiya, SW Kim, D Planchard, MJ Ahn, ... Journal of Clinical Oncology 41 (31), 4852-4863, 2023 | 106 | 2023 |
| Comparative analysis of durable responses on immune checkpoint inhibitors versus other systemic therapies: a pooled analysis of phase III trials E Pons-Tostivint, A Latouche, P Vaflard, F Ricci, D Loirat, S Hescot, ... JCO Precision Oncology 3, 1-10, 2019 | 104 | 2019 |
| STK11/LKB1 Modulation of the Immune Response in Lung Cancer: From Biology to Therapeutic Impact E Pons-Tostivint, A Lugat, JF Fontenau, MG Denis, J Bennouna Cells 10 (11), 3129, 2021 | 55 | 2021 |
| Survival impact of locoregional treatment of the primary tumor in de novo metastatic breast cancers in a large multicentric cohort study: a propensity score-matched analysis E Pons-Tostivint, Y Kirova, A Lusque, M Campone, J Geffrelot, C Mazouni, ... Annals of Surgical Oncology 26, 356-365, 2019 | 52 | 2019 |
| LBA12 Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III … MJ Ahn, A Lisberg, L Paz-Ares, R Cornelissen, N Girard, E Pons-Tostivint, ... Annals of Oncology 34, S1305-S1306, 2023 | 45* | 2023 |
| Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study … MJ Ahn, A Lisberg, L Paz-Ares, R Cornelissen, N Girard, E Pons-Tostivint, ... Annals of Oncology 34, S1305-S1306, 2023 | 34 | 2023 |
| 1314MO TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs) L Paz-Ares, MJ Ahn, AE Lisberg, S Kitazono, BC Cho, G Blumenschein, ... Annals of Oncology 34, S755-S756, 2023 | 33 | 2023 |
| Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with squamous cell carcinoma of the head and neck. K Saleh, A Daste, N Martin, E Pons-Tostivint, A Auperin, ... Journal of Clinical Oncology 36 (15_suppl), 6015-6015, 2018 | 30 | 2018 |
| Pancreatic cancer intrinsic PI3Kα activity accelerates metastasis and rewires macrophage component B Thibault, F Ramos‐Delgado, E Pons‐Tostivint, N Therville, C Cintas, ... EMBO molecular medicine 13 (7), e13502, 2021 | 29 | 2021 |
| Radiation therapy to the primary tumor for de novo metastatic breast cancer and overall survival in a retrospective multicenter cohort analysis E Pons-Tostivint, Y Kirova, A Lusque, M Campone, J Geffrelot, S Rivera, ... Radiotherapy and Oncology 145, 109-116, 2020 | 29 | 2020 |
| SAPPHIRE: Phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer H Borghaei, F de Marinis, D Dumoulin, C Reynolds, W Theelen, ... Annals of Oncology 35 (1), 66-76, 2024 | 26 | 2024 |
| Quality of life and functional outcomes after radical cystectomy with ileal orthotopic neobladder replacement for bladder cancer: a multicentre observational study V Tostivint, G Verhoest, B Cabarrou, J Gas, P Coloby, J Zgheib, ... World journal of urology 39, 2525-2530, 2021 | 26 | 2021 |
| Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial B Besse, E Pons-Tostivint, K Park, S Hartl, PM Forde, MJ Hochmair, ... Nature medicine 30 (3), 716-729, 2024 | 19 | 2024 |
| Multidisciplinary team meeting and EUSOMA quality indicators in breast cancer care: a French regional multicenter study E Pons-Tostivint, L Daubisse-Marliac, P Grosclaude, J Goddard, C Morel, ... The Breast 46, 170-177, 2019 | 19 | 2019 |
| Early locoregional breast surgery and survival in de novo metastatic breast cancer in the multicenter national ESME cohort J Hotton, A Lusque, L Leufflen, M Campone, C Levy, JF Honart, A Mailliez, ... Annals of Surgery 277 (1), e153-e161, 2023 | 16 | 2023 |
| Is there a role for locoregional treatment of the primary tumor in de novo metastatic breast cancer in the era of tailored therapies?: Evidences, unresolved questions and a … E Pons-Tostivint, E Alouani, Y Kirova, F Dalenc, C Vaysse Critical reviews in oncology/hematology 157, 103146, 2021 | 16 | 2021 |
